title: Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia.
abstract: Inducible nitric oxide synthase (iNOS) inhibition was recently shown to exert no effect on allergen challenge in human asthma, raising serious concerns about the role of the protein in the disease. The present study investigated the role of iNOS in ovalbumin-induced eosinophilia from the perspective of its relationship with poly(ADP-ribose) polymerase-1 (PARP-1) and oxidative DNA damage. A mouse model of ovalbumin-induced eosinophilia was used to conduct the studies. iNOS-associated protein nitration and tissue damage were partially responsible for allergen-induced eosinophilia. iNOS expression was required for oxidative DNA damage and PARP-1 activation upon allergen challenge. PARP-1 was required for iNOS expression and protein nitration, and this requirement was connected to nuclear factor-kappaB. PARP-1 was an important substrate for iNOS-associated by-products after ovalbumin-challenge. PARP-1 nitration blocked its poly(ADP-ribosyl)ation activity. Interleukin-5 re-establishment in ovalbumin-exposed PARP-1(-/-) mice reversed eosinophilia and partial mucus production without a reversal of iNOS expression, concomitant protein nitration or associated DNA damage. The present results demonstrate a reciprocal relationship between inducible nitric oxide synthase and poly(ADP-ribose) polymerase-1 and suggest that expression of inducible nitric oxide synthase may be dispensable for eosinophilia after interleukin-5 production. Inducible nitric oxide synthase may be required for oxidative DNA damage and full manifestation of mucus production. Such dispensability may explain, in part, the reported ineffectiveness of inducible nitric oxide synthase inhibition in preventing allergen-induced inflammation in humans.
authors.affiliation: Louisiana State University Health Sciences Center, Dept of Pharmacology and Experimental Therapeutics, 1901 Perdido St., New Orleans, LA 70112, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Naura
authors.forename: R
authors.initials: R
authors.lastname: Datta
authors.forename: C P
authors.initials: CP
authors.lastname: Hans
authors.forename: M
authors.initials: M
authors.lastname: Zerfaoui
authors.forename: B M
authors.initials: BM
authors.lastname: Rezk
authors.forename: Y
authors.initials: Y
authors.lastname: Errami
authors.forename: M
authors.initials: M
authors.lastname: Oumouna
authors.forename: K
authors.initials: K
authors.lastname: Matrougui
authors.forename: A H
authors.initials: AH
authors.lastname: Boulares
mesh_terms: D000485:Allergens / Q000378:metabolism; D000818:Animals; D004249:DNA Damage; D004802:Eosinophilia / Q000201:enzymology* / Q000378:metabolism; D015971:Gene Expression Regulation, Enzymologic; D015848:Interleukin-5 / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008856:Microscopy, Fluorescence; D008954:Models, Biological; D016328:NF-kappa B / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism*; D000071137:Poly (ADP-Ribose) Polymerase-1; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism*
chemical_list: D000485:Allergens; D015848:Interleukin-5; D016328:NF-kappa B; D052247:Nitric Oxide Synthase Type II; C499320:PARP1 protein, human; D000071137:Poly (ADP-Ribose) Polymerase-1; D011065:Poly(ADP-ribose) Polymerases